Epstein-Barr virus as a cause of multiple sclerosis: opportunities for prevention and therapy

Lancet Neurol. 2023 Apr;22(4):338-349. doi: 10.1016/S1474-4422(22)00471-9. Epub 2023 Feb 7.

Abstract

Multiple sclerosis is a chronic inflammatory disease of the CNS that results from the interplay between heritable and environmental factors. Mounting evidence from different fields of research supports the pivotal role of the Epstein-Barr virus (EBV) in the development of multiple sclerosis. However, translating this knowledge into clinically actionable information requires a better understanding of the mechanisms linking EBV to pathophysiology. Ongoing research is trying to clarify whether EBV causes neuroinflammation via autoimmunity or antiviral immunity, and if the interaction of EBV with genetic susceptibility to multiple sclerosis can explain why a ubiquitous virus promotes immune dysfunction in susceptible individuals. If EBV also has a role in driving disease activity, the characterisation of this role will help diagnosis, prognosis, and treatment in people with multiple sclerosis. Ongoing clinical trials targeting EBV and new anti-EBV vaccines provide hope for future treatments and preventive interventions.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Epstein-Barr Virus Infections* / complications
  • Epstein-Barr Virus Infections* / therapy
  • Herpesvirus 4, Human / genetics
  • Humans
  • Longitudinal Studies
  • Multiple Sclerosis* / etiology
  • Multiple Sclerosis* / prevention & control